Hydatid disease caused by Echinococcus granulosus (Eg), is one of the most important parasitic zoonosis in Uruguay, Argentina, Brasil, Chile and Perú. Economic losses in the cattle industry have been estimated at more than two billion dollars annually. Despite the socio-economic impact, hydatid disease remains a neglected zoonotic disease. In the last 5 decades, it has tried the generation of vaccines, obtaining little success. Tests on mice conducted by our research group, using recombinant Echinococcus granulosus Fatty acid binding protein (EgFABP1) and recombinant Echinococcus granulosus Tropomiosyn (EgTRP) expressed in Salmonella typhimurium as a vaccine, showed that the mouse was able to develop immune responses against antigens. In this research, we opted for the generation of polymeric nanoparticles (NPs) as distribution system. There are important advantages in the use of nanoparticles as a delivery system, highlighting the possibility of manipulating the size and surface characteristics of the nanoparticles to direct the compound to the site of action and the possibility of controlling and maintaining the release of the active compound during transportation and once at the action site. The overall objective of this research is to encapsulate EgFABP 1 r and EgTRP in NPs and evaluate its antigenicity in mice, as a first step towards the development of an oral nanovaccine against Eg, to be applied in the definitive host. We expect to develop nanocarriers for oral administration of antigens and evaluate it as a vaccine against Eg in dogs.